TIThe Environmental Data And Governance Initiative
The Environmental Data And Governance Initiative
+1
This article examines the history of risk assessments of the organophosphate pesticide chlorpyrifos at the US Environmental Protection Agency (EPA), especially after a ban on household uses in 2000. Federal funding enabled more noncorporate and place-based scientific investigations of this pesticide’s harms, including child-cohort epidemiology of populations impacted through environmental injustices. This article argues, first, that their findings challenged the thin knowledge base, mostly from corporate-sponsored toxicology, that originally justified chlorpyrifos’s continued use. Second, for decades, outside a court-induced interval in 2015–2016, EPA’s risk assessments favored “de-placed” toxicological modes and standards of knowledge—forged in the controlled environment of experimental laboratories—while marginalizing science gathered from the actual places and people EPA is supposed to protect. Third, agency officials stuck with a quantifiable, laboratory- and modeling-centered calculus for assessing health risks in part because a united front of corporate and corporate-consultant scientists harped on the uncertainties of newer findings. The article concludes that the agency needs to rethink its risk assessment practices and dependence, as well as more effectively account for financial conflicts of interest in evaluations of policy-relevant science. ( Am J Public Health. 2025;115(7):1074–1084. https://doi.org/10.2105/AJPH.2025.308073 )
How damaging was the Trump administration to environmental justice (EJ) efforts and policy? Since federal EJ oversight at the United States Environmental Protection Agency (EPA) is governed by executive order, rather than statute, approaches to it have varied by presidential administration. In this paper, we draw on interviews with current and recently retired EPA employees along with staffing and budget data, to examine how EJ has historically been supported and enacted within the agency, with a focus on identifying impacts of the Trump administration on EPA’s EJ work. We find that while leadership support for EJ and emphasis across the agency have changed across presidential administrations, the EJ program has always held a marginal position in terms of allocation of resources and emphasis in regulatory decision-making. Starting from this position of long-term marginalization, EPA’s EJ program was further marginalized by the Trump administration. Though EPA employees expressed divided opinions as to how consequential the Trump administration’s actions were on enacting EJ internally, many thought that the administration’s emphasis on deregulation had significant health consequences in EJ communities. We argue that the impacts of the Trump administration, like those of future administrations, must be assessed within a historical context.
8 July 2020 in American Journal of Industrial Medicine